Novo Nordisk: Undervalued Despite Strong Growth Trend & Solid Market Share

Novo Nordisk (NVO) is deemed undervalued despite its strong growth trajectory and dominant 62% global GLP-1 market share, underpinned by robust Ozempic sales and a diversified portfolio including Rybelsus. The company consistently demonstrates double-digit revenue and profit growth, with strong Q2 2025 expectations. An analyst notes NVO trades at a significant discount to Eli Lilly, implying nearly 38% upside, and rates the stock a 'buy' based on its market leadership and valuation.

Analysis

Novo Nordisk's dominant position in the rapidly expanding GLP-1 market is underscored by its 62% global market share, primarily driven by the strength of its flagship product, Ozempic. The company's strategic advantage is further solidified by a diversified product portfolio, which includes Rybelsus and anticipated oral formulations, broadening its addressable market and creating a buffer against competitive pressures from peers like Eli Lilly. This market leadership is complemented by strong financial performance, characterized by consistent double-digit growth in both revenue and profit, and a positive outlook with strong expectations for Q2 2025. From a valuation perspective, the analysis highlights a significant discount relative to its key peer, Eli Lilly, suggesting a potential upside of nearly 38% and forming the basis for the 'buy' recommendation.

Key Decisions for Investors

• Given the company's 62% global GLP-1 market share and consistent double-digit growth, investors could view the noted 38% valuation discount to Eli Lilly as a potential entry point, contingent on continued strong performance.
• The competitive moat and future growth depend significantly on the company's diversified portfolio; therefore, closely monitoring the progress and market reception of its pipeline, including Rybelsus and future oral formulations, is critical.
• As the 'undervalued' thesis is based on a direct comparison to Eli Lilly, it is prudent to analyze the relative performance and fundamentals of both companies, as a change in LLY's valuation or outlook could directly impact NVO's perceived upside.